TELESTA THERAPEUTICS INC T.TST

yankee- you make a good point

[NoNukNuk]

There would be a big difference in what a partner would pay for a chunk or urocidin as an orphan drug versus a drug needed by 200,000. what a blind spot by management to persue orphan status.

[DamnYankees]

I read between the lines of the recent Orphan status news item and it tells me that the FDA forsees a market for Urocidin that is infinitely larger than what Bioniche is letting on. That is not to say that the drug will be approved but it looks like there is quite a significan gap between what was the market potential in the submission and what the FDA and Bionicheor their potential partners are

[bailmeout]

I'm seeing it as a positive that the Orphan status was denied ..it's basically saying "No you are much bigger than that"..it is like telling the winner they don't qualify for the consolation prize :)

[IWillRetireSoon]

Sometimes research can be a simple process.   Website of American Bladder Cancer society states: Facts In the United States there were approximately 535,000 men and women alive who had a history of cancer of the urinary bladder -- 395,000 men and 140,000 women.   I have no idea of how many of those would benefit from Urocidin.    I just know that 535,000 is a lot

[DamnYankees]

Retire soon, are you a novice to the biotech world? The period between now and the submission date is when a partnership will happen. The trial data is public and the only unflipped card is market size. Once that is determined partnership discussioms should start to froth over. A partnership cost in this stage is negligeable compared to the 3000% premium that would be paid with an FDA approval

[IWillRetireSoon]

I may be a "novice" of sorts to biotech, but I am a very experienced investor with 40 years of investing and 30 years as tax accounting. The bean counters in big pharma are the same ones as any business with their risk tolerance.  Sure some companies are more willing to take risks with not yet approved drugs but most of the enterprises I have invested in would rather pay a

[rgonlyfactspls]

I believe the simple explanation is... much of this larger market is still treatable with BCG. BCG sells at a fraction of the price of what is proposed for MCNA. MCNA is targeted at BCG-refractory patients (tough challenge). There is virtually no competition for this subset (excluding Valstar, by Endo, with its marginal efficacy and only for treatment of CIS tumours). So a much smaller market for

[txbioinv]

RG, you are correct; prescribing therapies/medication/MCNA off-label will happen and its legal. Some institutions do not let certain medications be prescribed off-label such as medications for chronic pain. When I was getting treatment at Brooke Army Medical Center; they started enforcing only label use for chronic pain medications, which wasn't to the satisfaction of doctors who worked in the

[CasusFortuitus]

txbioinv wrote: When bladder cancer patients do their own research, they will demand MCNA as their first line therapy; its will be the future 'Gold Standard. Apparently you haven't heard of Theralase- V.TLT . If there's a future gold standard in bladder cancer treatment, it's Theralase. Bioniche's Urocidin is exactly that- a biological "niche" or "specialty"

[DamnYankees]

They have made some impressive progress in mice. While they have the same market capitalization as Bioniche their patients are still rodents. MCNA has cured cancer in a small town's population of humans, many of whom may otherwise die,with no side effects.and they are submitting for a marketing license with the FDA in March. The most interesting thing about TLT is that their pre clinical work

[CasusFortuitus]

That's because they also have a working, revenue generating arm that deals with therapeutic lasers.

[txbioinv]

[txbioinv]

Casus, you are right, as I have never heard of Theralase. By the time they even contemplate a phase 2 trail, our little future of a goldmine Telesta will be long gone as a stand alone biotech with MCNA achieving over half a billion in annual sales. GL serious longs

[CasusFortuitus]

--  Which is exactly why I am here looking for an entry point. There's no reason not to ride them both into the wild blue yonder.

[1wascallywabbit]

What are you waiting for - most of us here are in at an ACB of much higher than where we are now, most in multiples of the current price - some of us need over $1 if they have not averaged down. We would be so envious to be in your shoes right now if you don't have any at this point. I have well into 6 figures of Shares, and I need almost a double from here, so my paper loss is substantial